A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
NCT01201915 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74
Last updated 2014-06-24
Summary
This was a 3-cohort, open-label study of vismodegib (GDC-0449) in new (non-recurrent) operable basal cell carcinoma of the nodular subtype.
Conditions
Interventions
- DRUG
-
Vismodegib
Vismodegib was supplied in gelatin capsules.
Sponsors & Collaborators
-
Genentech, Inc.
lead INDUSTRY
Principal Investigators
-
Ivor Caro, M.D. · Genentech, Inc.
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-10-31
- Primary Completion
- 2013-05-31
- Completion
- 2013-05-31
Countries
- United States
Study Locations
More Related Trials
-
Vismodegib in Treating Patients With Advanced Chondrosarcomas
NCT01267955 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)
NCT02674009 ·Status: COMPLETED
-
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
NCT01154452 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
NCT06016920 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors
NCT02366312 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
NCT03107182 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Sorafenib/Cetuximab in Head and Neck Cancer
NCT00815295 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT01602315 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer
NCT06959082 ·Status: RECRUITING ·Phase: PHASE2
-
Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer
NCT07065630 ·Status: RECRUITING ·Phase: PHASE2
-
Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer
NCT03838263 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-Modulated Sonidegib Therapy for Periocular Basal Cell Carcinoma
NCT07068568 ·Status: COMPLETED
-
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
NCT02164461 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma
NCT03534947 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
NCT03786081 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base
NCT07145931 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy
NCT00116909 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
NCT05798819 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180 ·Status: RECRUITING ·Phase: PHASE3
-
TumorGraft- Guided Therapy for Improved Outcomes in Head and Neck Squamous Cell Cancer- A Feasibility Study
NCT02752932 ·Status: COMPLETED ·Phase: NA
-
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
NCT04193293 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
NCT01911598 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
NCT01577173 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
NCT07063212 ·Status: RECRUITING ·Phase: PHASE2
-
Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy
NCT02216916 ·Status: UNKNOWN ·Phase: PHASE2